Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 200 Results
Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust
Researchers found that while most patient organizations were initially unaware of real-world evidence (RWE) and its actual or potential uses, they recognized the ability of RWE to provide relevant…
Patients on RWE: WIIFM? (What’s In It for Me?)
In an article published in The Patient, NPC and the National Health Council found that while most patients were initially unaware of real-world evidence (RWE) and its actual or potential uses,…
NPC in Chain Drug Review: Let’s Address Health System Improvements in 2019
In his latest column for Chain Drug Review, National Pharmaceutical Council President and Chief Executive Officer Dan Leonard looks deeper into 2019 and explores how we can take a more…
Study: Investment in Treatment for Select Conditions Pays Off
Is increased health spending on medical interventions a good investment? This study explored the question.
What's Been the Bang for the Buck? Cost-Effectiveness of Health Care Spending Across Selected Conditions in the US
This study was designed to assess whether increased medical intervention spending on prevalent chronic conditions has been a good investment over time.
What Do Consumers Decide to Prioritize in Health Spending?
By Lisabeth Buelt, Research Manager, NPC
Celgene EVP Richard Bagger Elected National Pharmaceutical Council Board Chair
The NPC Board of Directors has named Celgene EVP Richard Bagger as Chairman for 2018-19.
Prioritizing Health Care Spending: Engaging Employees in Health Care Benefit Design
A case study shows that employees who are who are meaningfully engaged in deliberating and designing their health care benefits may have a more positive view of their coverage options.
NPC’s Dubois Named to Health Affairs Council on Health Care Spending and Value
Leading health policy journal Health Affairs announced the members of its Council on Health Care Spending and Value, a group of diverse health care thought leaders focused on examining the different…
Going Below the Surface E-Newsletter: September 2018
In this issue, we explore incentives in hospital and physician care.
National Pharmaceutical Council to CVS: Join Us in a Broader Dialogue to Address Health Care Spending
The viewpoints published on the Health Affairs Blog bring an important question to mind: will CVS join the National Pharmaceutical Council and key stakeholders from across the health sector in our…